The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combination chemotherapy with nintedanib/placebo for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN1/FANDANGO trial.
 
Mansoor Raza Mirza
No Relationships to Disclose
 
Johanna Unelma Maenpaa
No Relationships to Disclose
 
Elena Ioana Braicu
No Relationships to Disclose
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Biogen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Fresenius (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hampton Medical Conferences (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Kendle (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Quintiles (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst); Sigma-Tau (Inst); Telik (Inst); TRM Oncology (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Proacta (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche
 
Dominique Berton-Rigaud
No Relationships to Disclose
 
Per Rosenberg
No Relationships to Disclose
 
Jens Bodo Huober
No Relationships to Disclose
 
Hannelore Denys
No Relationships to Disclose
 
Florence Joly Lobbedez
No Relationships to Disclose
 
Gunnar Kristensen
No Relationships to Disclose
 
Toralf Reimer
No Relationships to Disclose
 
Frederic Kridelka
No Relationships to Disclose
 
Anne Floquet
No Relationships to Disclose
 
Anja Knudsen
No Relationships to Disclose
 
Bahriye Aktas
No Relationships to Disclose
 
Jean-Francois Baurain
No Relationships to Disclose
 
Philippe Follana
No Relationships to Disclose
 
Trine Juhler-Nøttrup
Consulting or Advisory Role - Advaxis
Travel, Accommodations, Expenses - Roche
 
Christina Jederud
No Relationships to Disclose
 
Jalid Sehouli
No Relationships to Disclose